Real-World Effectiveness of Biologic Therapy in Patients with Psoriasis: Metabolic Comorbidities and Treatment Outcomes
References
- SKAYEM C., TAIEB C., HALIOUA B., BAISSAC C., SAINT AROMAN M. Epidemiology of Psoriasis: A Worldwide Global Study. Acta Derm Venereol. 2025;105:adv42945.
- UNTAAVEESUP S., KANTAGOWIT P., UNGPRASERT P., KITLERTBANCHONG N., VAJIRAVIROJ T., SUTITHAVINKUL T., et al. The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14(4):1374.
- PARISI R., ISKANDAR IYK., KONTOPANTELIS E., AUGUSTIN M., GRIFFITHS CEM., ASHCROFT DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
- GRIFFITHS CEM., ARMSTRONG AW., GUDJONSSON JE., BARKER JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.
- COSTACHE DO., FEROIU O., GHILENCEA A., GEORGESCU M., CĂRUNTU A., CĂRUNTU C., et al. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. Int J Mol Sci. 2022;23(9):5198.
- COSTACHE D., BLEJAN H., POENARU M., COSTACHE R. Skin Cancer Correlations in Psoriatic Patients. Cancers (Basel). 2023;15(9):2451.
- GHILENCEA A., BLEJAN H., COSTACHE D., ENACHE A., CARUNTU C., SCHEAU C. Immunomodulatory Treatment Strategies in Psoriasis Patients with High-Risk Systemic Comorbidities: A Narrative Review and Case Series. Rom J Mil Med. 2026;CXXIX(3).
- BOEHNCKE WH., SCHÖN MP. Psoriasis. Lancet. 2015;386(9997):983–94.
- ARMSTRONG AW., READ C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA. 2020;323(19):1945.
- GISONDI P., TARGHER G., ZOPPINI G., GIROLOMONI G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–64.
- COSTACHE RS., GEORGESCU M., GHILENCEA A., FEROIU O., TIPLICA SG., COSTACHE DO. The Role of Inflammation in the Pathogenesis of Psoriasis. Rom J Mil Med. 2023;126(3):245–53.
- GHILENCEA AF., COJOCARU DL., POENARU M., COSTACHE RS., COSTACHE DO., CARUNTU C. The Effect of Biological Therapies on Psoriasis and Its Associated Comorbidities – New Facts and Future Options. Rom J Mil Med. 2025;128(4):318–24.
- COSTACHE D., BLEJAN H., COJOCARU D., IONIȚĂ G., POENARU M., CONSTANTIN M., et al. Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet—A Comprehensive Review. Int J Mol Sci. 2024;25(5):2660.
- CANDIA R., RUIZ A., TORRES-ROBLES R., CHÁVEZ-TAPIA N., MÉNDEZ-SÁNCHEZ N., ARRESE M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–62.
- JAMES L., DIAMOND C., AL-MOSSAWI H., ANDERSSON A., PANDYA P., SHUMBAYAWONDA E., et al. High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging. Rheumatology. 2025;64(11):5741–50.
- DONS M., NÄSLUND-KOCH C., SENGELØV M., BØGH-SØRENSEN S., SKAARUP KG., LØVENDORF MB., et al. Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiac manifestations in psoriasis: A cross-sectional study of 255 patients. J Intern Med. 2026;299(2):283–99.
- BUZZETTI E., PINZANI M., TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48.
- TILG H., MOSCHEN AR. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology. 2010;52(5):1836–46.
- EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. Corrigendum to “EASL recommendations on treatment of hepatitis C: Final update of the series” [J Hepatol 73 (2020) 1170–1218]. J Hepatol. 2023;78(2):452.
- MENTER A., STROBER BE., KAPLAN DH., KIVELEVITCH D., PRATER EF., STOFF B., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
- MEHTA NN., AZFAR RS., SHIN DB., NEIMANN AL., TROXEL AB., GELFAND JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6.
- EGEBERG A., ROSENØ NAL., THEIN D., LØRUP EH., NIELSEN ML., NYMAND L., et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.
- WARREN RB., SMITH CH., YIU ZZN., ASHCROFT DM., BARKER JNWN., BURDEN AD., et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40.
- DING Q., PUIG L., FAN T., SMITH N. Predictors of biologic treatment of psoriasis: a non-interventional study. Clin Outcomes Res. 2014;6:93.
- BAI F., LI GG., LIU Q., NIU X., LI R., MA H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019;2019:1–25.
- ZHOU XD., CAI J., TARGHER G., BYRNE CD., SHAPIRO MD., SUNG KC., et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270.
DOI: https://doi.org/10.2478/rjim-2026-0020 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749
Language: English, Romanian
Submitted on: Jun 3, 2026
Published on: Sep 23, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Adelina F. Ghilencea, Daniel O. Costache, Constantin Căruntu, Cristian Scheau, Ilinca Savulescu-Fiedler, Ioana Dicu-Andreescu, Damian Cojocaru, Raluca S. Costache, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 License.